Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system

Jan M. Griffin, Ersilia M. DeFilippis, Hannah Rosenblum, Veli K. Topkara, Justin A. Fried, Nir Uriel, Koji Takeda, Maryjane A. Farr, Mathew S. Maurer, Kevin J. Clerkin

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


The new heart transplantation (HT) allocation policy was introduced on 10/18/2018. Using the UNOS registry, we examined early outcomes following HT for restrictive cardiomyopathy, hypertrophic cardiomyopathy, cardiac sarcoidosis, or cardiac amyloidosis compared to the old system. Those listed who had an event (transplant, death, or waitlist removal) prior to 10/17/2018 were in Era 1, and those listed on or after 10/18/2018 were in Era 2. The primary endpoint was death on the waitlist or delisting due to clinical deterioration. A total of 1232 HT candidates were included, 855 (69.4%) in Era 1 and 377 (30.6%) in Era 2. In Era 2, there was a significant increase in the use of temporary mechanical circulatory support and a reduction in the primary endpoint, (20.9 events per 100 PY (Era 1) vs. 18.6 events per 100 PY (Era 2), OR 1.98, p =.005). Median waitlist time decreased (91 vs. 58 days, p <.001), and transplantation rate increased (119.0 to 204.7 transplants/100 PY for Era 1 vs Era 2). Under the new policy, there has been a decrease in waitlist time and waitlist mortality/delisting due to clinical deterioration, and an increase in transplantation rates for patients with infiltrative, hypertrophic, and restrictive cardiomyopathies without any effect on post-transplant 6-month survival.

Original languageEnglish (US)
Article numbere14109
JournalClinical Transplantation
Issue number12
StatePublished - Dec 2020
Externally publishedYes


  • amyloidosis
  • cardiac sarcoidosis
  • heart transplantation
  • restrictive cardiomyopathy
  • waitlist

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system'. Together they form a unique fingerprint.

Cite this